Zolpidem is a short-acting imidazopyridine hypnotic that binds at the benzodiazepine binding site on specific GABA A receptors to enhance fast inhibitory neurotransmission. The behavioral and receptor pharmacology of zolpidem has been studied extensively, but little is known about its neuronal substrates in vivo. In the present within-subject, double-blind, and placebo-controlled study, blood oxygen level-dependent functional magnetic resonance imaging (BOLD fMRI) at 3 Tesla was used to assess the effects of zolpidem within the brain. Healthy participants (n = 12) were scanned 60 min after acute oral administration of zolpidem (0, 5, 10, or 20 mg), and changes in BOLD signal were measured in the visual cortex during presentation of a flashing checkerboard. Heart rate and oxygen saturation were monitored continuously throughout the session. Zolpidem (10 and 20 mg) reduced the robust visual system activation produced by presentation of this stimulus, but had no effects on physiological activity during the fMRI scan. Zolpidem's modulation of the BOLD signal within the visual cortex is consistent with the abundant distribution of GABA A receptors localized in this region, as well as previous studies showing a relationship between increased GABA-mediated neuronal inhibition and a reduction in BOLD activation.
Introduction
Zolpidem (Ambien®) is a short-acting imidazopyridine hypnotic that increases GABA-mediated inhibition via positive allosteric modulation at the benzodiazepine binding site on specific GABA A receptors (Tallman et al., 1978) . Although the typical sedativehypnotic effects of zolpidem have been well documented in both laboratory animals (e.g., Sanger et al., 1987) and humans (see review by Rush, 1998), only a handful of studies have employed imaging to understand zolpidem's neurobiological substrates in vivo. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) have shown that in neurologically abnormal humans (Brefel-Courbon et al., 2007; Clauss et al., 2000 Clauss et al., , 2004 Cohen et al., 2004; Hall et al., 2010) and baboons (Clauss et al., 2001 (Clauss et al., , 2002 , zolpidem increased cerebral perfusion in areas that were hypoactive as a result of brain injury. Otherwise, frontal reductions in brain metabolism (Brefel-Courbon et al., 2007) or an absence of druginduced changes in brain perfusion (Clauss et al., 2001) were observed. In healthy humans during sleep, zolpidem reduced cerebral glucose metabolism (Gillin et al., 1996) and cerebral blood flow (CBF; Finelli et al., 2000) in a number of frontal regions including white matter and anterior cingulate, as well as basal ganglia, insula, and hippocampus. Simultaneously, zolpidem administration also increased CBF to regions such as parietal and occipital cortices, parahippocampal gyrus, and cerebellum (Finelli et al., 2000) , collectively suggesting a complex action in vivo.
To date, no studies have used functional magnetic resonance imaging (fMRI) to investigate zolpidem's effect on brain function in awake, healthy humans. Like PET and SPECT, fMRI provides indirect measures of neuronal activity depending on cerebral oxygenation, blood flow, and blood volume. Typically, changes in the blood oxygen level-dependent (BOLD) signal are used to visualize the relationship between the brain's hemodynamic response to a stimulus and presumed changes in neuronal activity. In the present study, fMRI correlates of zolpidem's action were investigated. It was hypothesized that based on previous studies showing a relationship between increased GABA-mediated neuronal inhibition and a reduction in the BOLD signal (Chen et al., 2005; Donahue et al., 2010; Muthukumaraswamy et al., 2009 Muthukumaraswamy et al., , 2011 Northoff et al., 2007) , zolpidem would reduce BOLD activation similarly due to its GABA-enhancing pharmacological effects. Specifically, BOLD 
